Quince Therapeutics(NASDAQ) CRTX

Market CapN/A

Since IPO (2019)-99%

5 Year-100%

1 Year-90%

1 Month+81%

N/A

Quince Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 34.12	2026-08-17

Quince Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+11.32%	USD 30.65	2026-08-10
1 month	+80.72%	USD 18.88	2026-07-17
3 month	+59.44%	USD 21.40	2026-05-19
Year to date	-94.91%	USD 670.00	2025-12-31
1 year	-89.91%	USD 338.00	2025-08-15
3 year	-86.57%	USD 254.00	2023-08-18
5 year	-99.81%	USD 17,828.00	2021-08-18
Since inception	-99.48%	USD 6,578.00	2019-05-09

Quince Therapeutics Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

-$92.48M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 8, 2022

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 8, 2022

CRTX News

falling chart man watching computer screen

Is This Under-the-Radar Stock Set to Succeed in Alzheimer's Disease?

David HaenFeb 7, 2020

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Quince Therapeutics

Quince develops drug delivery technology for rare diseases. Its main platform uses a patient’s own blood cells to carry medicine. This approach aims to help people with hard-to-treat conditions by targeting drugs more precisely.

What’s in the Quince Toolbox?

AIDE Platform: Encapsulates drugs inside a patient’s red blood cells for targeted delivery (0% of revenue).
eDSP: Drug candidate for ataxia-telangiectasia, a rare genetic disorder; development stopped after failed trial (0% of revenue).
RCL Device: Machine that loads drugs into blood cells at the treatment site (0% of revenue).
Treatment Kits: Single-use kits for use with the RCL device in clinics (0% of revenue).
Intellectual Property: Patents covering the AIDE platform and related technologies.

Growth and Expansion: The Quince Timeline

Changed name from Cortexyme to Quince in August 2022 to reflect new focus.
Completed Phase 3 trial for eDSP in January 2026; trial did not meet goals.
Discontinued all research and development activities in early 2026.
Engaged LifeSci Capital in February 2026 to explore strategic alternatives, including a reverse merger.
Settled EIB Loan for $5.5 million in March 2026.

What Makes Quince Stand Out?

Quince’s technology uses a patient’s own blood cells to deliver drugs, aiming for fewer side effects. The company holds patents in the US, Europe, and Japan. Its in-house manufacturing in Italy meets both US and EU standards.

Five Things You Need to Know

No revenue reported for 2023, 2024, or 2025.
Net loss was $13 million in Q3 2025, down 144.8% from Q3 2024.
Cash and short-term investments totaled $17.8 million at December 31, 2025.
Operating expenses were $58.07 million in 2025, up 1% from 2024.
Company is seeking a merger or sale after stopping all product development.

Bottom Line

Quince shifted from drug development to seeking strategic options after its main product failed. The company now focuses on preserving cash and exploring a possible merger or sale.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Dirk Thye, MD

Website

quincetx.com

Headquarters

South San Francisco, CA 94080, US

CRTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

681.14%

Return on Capital

N/A

Return on Assets

-74.58%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$59.04M

Operating Income

-$127.16M

EBITDA

-$48.70M

Operating Cash Flow

-$53.41M

Capital Expenditure

$65.00K

Free Cash Flow

-$53.35M

Cash & ST Invst.

$115.98M

Total Debt

$0.00

Quince Therapeutics Performance Analysis

Quince Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

Quince Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A
Q2	2026-06-30	N/A

Quince Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -308.45	-49.0%
2023	2023-12-31	USD -168.57	-45.3%
2024	2024-12-31	USD -262.71	55.9%
2025	2025-12-31	USD -335.27	27.6%

Quince Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	26.5%
Q4	2025-12-31	-200.0%
Q1	2026-03-31	484.0%
Q2	2026-06-30	-527.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$59.00M

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$75.49M

-370.4%

EBITDA

-$79.78M

-400.1%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$115.98M

+234.2%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$0.00

N/A

Return on Assets

-74.58%

N/A

Return on Invested Capital

-57.13%

N/A

Free Cash Flow

-$18.89M

-263.6%

Operating Cash Flow

-$18.89M

-283.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SURFSurface Oncology, Inc.

SURFSurface Oncology, Inc.$1.07-0.93%

ACHLAchilles Therapeutics plc

ACHLAchilles Therapeutics plc$1.48+0.68%

LABPLandos Biopharma, Inc.

LABPLandos Biopharma, Inc.$22.93+0.57%

JBIOJade Biosciences, Inc.

JBIOJade Biosciences, Inc.$23.55+0.43%

RPHMReneo Pharmaceuticals, Inc.

RPHMReneo Pharmaceuticals, Inc.$18.20+952.02%

IGMSIGM Biosciences, Inc.

IGMSIGM Biosciences, Inc.$1.27+0.00%

TCRRTCR2 Therapeutics Inc.

TCRRTCR2 Therapeutics Inc.$1.48+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$8.48-0.02%

INTCIntel

INTCIntel$96.69-0.07%

NOKNokia

NOKNokia$10.39-0.04%

NVDANvidia

NVDANvidia$219.74-0.02%

PATHUiPath

PATHUiPath$15.58-0.03%

NUNu Holdings

NUNu Holdings$14.35-0.03%

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$129.10-0.15%

Questions About CRTX

What is the current price of Quince Therapeutics?

Quince Therapeutics is trading at N/A per share.

What is the 52-week range for Quince Therapeutics?

Over the past 52 weeks, Quince Therapeutics has traded between N/A and N/A.

How much debt does Quince Therapeutics have?

As of the most recent reporting period, Quince Therapeutics reported total debt of $0.00.

How much cash does Quince Therapeutics have on hand?

Quince Therapeutics reported $115.98M in cash and cash equivalents in its most recent financial results.

What is Quince Therapeutics’s dividend yield?

Quince Therapeutics does not currently have a dividend yield.

Quince Therapeutics(NASDAQ) CRTX

Quince Therapeutics Financials at a Glance

CRTX News

Why Cortexyme's Stock Is Crashing Today

2 Short-Squeeze Candidates That Could Go Parabolic Soon

Down 76%: Is Cortexyme Stock a Bargain?

Cortexyme's Alzheimer's Drug Fails -- 2 Lessons for Investors

Here's Why Cortexyme Is Imploding on Wednesday

Is This Under-the-Radar Stock Set to Succeed in Alzheimer's Disease?

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Quince Therapeutics

What’s in the Quince Toolbox?

Growth and Expansion: The Quince Timeline

What Makes Quince Stand Out?

Five Things You Need to Know

Bottom Line

CRTX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Quince Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CRTX

What is the current price of Quince Therapeutics?

What is the 52-week range for Quince Therapeutics?

How much debt does Quince Therapeutics have?

How much cash does Quince Therapeutics have on hand?

What is Quince Therapeutics’s dividend yield?

Premium Investing Services